...
首页> 外文期刊>Statistics in medicine >A composite design for transition from a preliminary to a full-scale study.
【24h】

A composite design for transition from a preliminary to a full-scale study.

机译:从初步研究到全面研究的综合设计。

获取原文
获取原文并翻译 | 示例
           

摘要

In drug development, a sequence of studies are conducted to evaluate effectiveness (or efficacy) and safety, such as a Phase II study to assess pharmacological activity or safety that is then followed by a definitive Phase III study to assess clinical effectiveness. Rather than conducting separate successive studies, we describe a design in which the patients enrolled in a preliminary (e.g. Phase II) study are continued into a subsequent full-scale (e.g. Phase III) study. This design also applies to a study that uses an internal pilot with a preliminary assessment of efficacy or safety. The combined preliminary to full-scale design potentially reduces the total numbers of patients required and the total duration of the program. The design allows a futility or safety stopping boundary for the preliminary study result that is specified in terms of a lower critical Z-value (Z(L)) and the pursuant type II error probability incurred under a specified alternative hypothesis of a beneficial effect or no toxicity at that stage. This boundary also leads to a deflation of the type I error probability for the final test at the completion of the full-scale study, such that a critical value for the final test (Z(F)) can be determined that provides the desired level of the type I error probability exactly. Thus, it is possible to determine sample sizes at the two stages, and critical values Z(L) and Z(F) that provide specified type I and II error probabilities for the combined study. We describe the design using large-sample normally distributed Z-tests at the two phases, including a test for means, or proportions or survival times, or combinations thereof, such as a test for means at Phase II followed by a test for proportions at Phase III. We compare the properties of this design versus the conduct of two successive studies, and explore the factors that influence the operating characteristics of the design. We also discuss the practical considerations in the implementation of the design.
机译:在药物开发中,进行了一系列研究以评估有效性(或功效)和安全性,例如进行II期研究以评估药理活性或安全性,然后进行确定的III期研究以评估临床有效性。我们没有进行单独的连续研究,而是描述了一种设计,在该设计中,将参与初步研究(例如II期)的患者继续进行到随后的全面研究(例如III期)中。该设计还适用于使用内部飞行员进行疗效或安全性初步评估的研究。初步设计到全面设计的组合可能会减少所需患者的总数和计划的总持续时间。该设计允许以较低的临界Z值(Z(L))和在特定的替代假设下产生有益效应而产生的II类错误概率来指定初步研究结果的无效性或安全性停止边界。在那个阶段没有毒性。此边界还会导致在完成全面研究后最终测试的I型错误概率降低,从而可以确定最终测试的临界值(Z(F)),以提供所需的水平完全是I型错误概率。因此,有可能确定两个阶段的样本量以及临界值Z(L)和Z(F),这些临界值可为组合研究提供指定的I型和II型误差概率。我们在两个阶段使用大样本正态分布Z检验来描述设计,包括均值,比例或生存时间的测试,或其组合,例如第二阶段的均值测试,然后是第二阶段的均值测试第三阶段。我们将这种设计的特性与两次连续研究的进行进行比较,并探讨影响设计工作特性的因素。我们还将讨论设计实施中的实际考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号